Core Viewpoint - The company, Lihe Kechuang (002243.SZ), has announced that it is currently not participating in the Shaoguan computing power center project due to the current market environment and its overall strategic layout [1] Group 1 - The company has made a strategic decision not to engage in the Shaoguan computing power center project [1]

2026年第二次临时股东会决议公告 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002243 证券简称：力合科创 公告编号：2026-006号 深圳市力合科创股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、特别提示 （一）公司于2026年1月22日在《证券时报》《上海证券报》及巨潮资讯网上刊登了《关于召开2026年 第二次临时股东会的通知》； （二）本次股东会无增加、变更、否决议案的情况； （三）本次股东会以现场投票和网络投票表决相结合的方式召开； （四）为了保障中小投资者权益，提高中小投资者对公司股东会决议的重大事项参与度，本次股东会审 议的议案均对中小投资者单独计票。 二、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为2026年2月6日9:15一9:25，9:30一11:30和13:00 一15:00。 通过深圳证券交易所互联网投票系统投票的开始投票的时间为2026年2月6日9:15，结束时间为2026年2 月6日15:00。 2、会议地点： 深圳市南山区科技 ...

证券代码：002243 证券简称：力合科创 公告编号：2026-006 号 深圳市力合科创股份有限公司 2026 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示 （一）公司于 2026 年 1 月 22 日在《证券时报》《上海证券报》及巨潮资讯网上 刊登了《关于召开 2026 年第二次临时股东会的通知》； （二）本次股东会无增加、变更、否决议案的情况； （三）本次股东会以现场投票和网络投票表决相结合的方式召开； （四）为了保障中小投资者权益，提高中小投资者对公司股东会决议的重大事项 参与度，本次股东会审议的议案均对中小投资者单独计票。 二、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议：2026 年 2 月 6 日 14:30 （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2026 年 2 月 6 日 9:15 —9:25，9:30—11:30 和 13:00—15:00。 4、会议召集人：公司董事会 1 5、会议主持人：董事长贺臻先生 本次会议的召集和召开符合《 ...

中国 深圳 福田区 益田路6001号太平金融大厦11、12层 邮政编码：518038 11&12/F., TaiPing Finance Tower, NO. Yitian Road 6001, Futian District，ShenZhen, P.R. CHINA 电话(Tel.)：(0755) 88265064, 88265288 传真(Fax.)：(0755)83243108 网址（Website）：http://www.sundiallawfirm.com 广东信达律师事务所 关于深圳市力合科创股份有限公司 二〇二六年第二次临时股东会的法律意见书 信达会字(2026)第023号 致：深圳市力合科创股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《上市公司股东会 规则》（下称"《规则》"）等法律、法规、规范性文件以及现行有效的《深圳市 力合科创股份有限公司章程》（下称"《公司章程》"）的规定，广东信达律师事 务所（下称"信达"）接受深圳市力合科创股份有限公司（下称"贵公司"）的委 托，指派律师参加贵公司2026年第二次临时股东会（下称"本次股东会"），在进 行必要验证工作的基础上，对 ...

Group 1 - The major shareholder, Lihe Kechuang, plans to reduce its stake in Huajin Capital by a total of up to 10.34 million shares, representing 3% of the total share capital, between November 7, 2025, and February 4, 2026 [1] - As of February 4, 2026, the reduction plan has resulted in a cumulative decrease of 3.447 million shares, which is 1% of the total share capital [1] - After the reduction, Lihe Kechuang's holdings will decrease to 23.8402 million shares, accounting for 6.92% of the total share capital [1] Group 2 - The reduction is driven by operational development needs and does not violate any relevant regulations [1] - The share reduction will not lead to a change in the company's control [1]

（文章来源：证券日报） 证券日报网讯 2月3日，力合科创在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东户 数为39052户。 ...

Core Viewpoint - The professional services sector experienced a decline of 0.84% on January 28, with notable losses from Su Shi Testing, while the Shanghai Composite Index rose by 0.27% to close at 4151.24 [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up 0.09% [1]. - The professional services sector saw a net outflow of 1.03 billion yuan from major funds, while retail investors contributed a net inflow of 1.24 billion yuan [2][3]. Group 2: Individual Stock Performance - Xince Standard (300938) led the gains with a closing price of 36.20, up 8.38% and a trading volume of 261,100 shares, totaling 922 million yuan [1]. - Guangdong Jian Ke (301632) closed at 26.99, up 4.17%, with a trading volume of 118,200 shares, totaling 314 million yuan [1]. - Su Shi Testing (300416) faced the largest decline, closing at 19.31, down 4.22% with a trading volume of 306,500 shares, totaling 598 million yuan [2]. Group 3: Fund Flow Analysis - Major funds showed a net inflow of 74.08 million yuan into Xince Standard (300938), while retail investors had a net outflow of 25.35 million yuan [3]. - Zhonggang Tianyuan (002057) saw a net inflow of 29.79 million yuan from major funds, with retail investors experiencing a net outflow of 841.16 million yuan [3]. - The overall trend indicates that while major funds are withdrawing, retail investors are actively participating in the market [2][3].

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Group 1 - The core point of the article is that Lihua Science and Technology (002243) reported a total of 39,529 shareholders as of January 20, 2026 [1]

深圳市力合科创股份有限公司 独立董事候选人声明与承诺 声明人 刘永 作为深圳市力合科创股份有限公司第六届董事会独立 董事候选人，已充分了解并同意由提名人深圳清研投资控股有限公司提名 为深圳市力合科创股份有限公司（以下简称该公司）第六届董事会独立董 事候选人。现公开声明和保证，本人与该公司之间不存在任何影响本人独立 性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券 交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并 承诺如下事项： 一、本人已经通过深圳市力合科创股份有限公司第六届董事会提名委 员会资格审查，提名人与本人不存在利害关系或者其他可能影响独立履职 情形的密切关系。 √ 是 □ 否 如否，请详细说明： √ 是 □ 否 如否，请详细说明： 四、本人符合该公司章程规定的独立董事任职条件。 √ 是 □ 否 如否，请详细说明： 五、本人已经参加培训并取得证券交易所认可的相关培训证明材料 （如有）。 √是 □ 否 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不 得担任公司董事的情形。 √ 是 □ 否 如否，请详细说明： 三、本人符合中国证监会《上市公司独立董事管理办法 ...